PolyPeptide Group (PPGN.SW) Stock Price
PolyPeptide Group Price
Revenue has compounded at 11.4% per year over the past 7 years to 351.35 M EUR. Earnings per share have declined at 25.0% per year over the last 4 years. PolyPeptide Group's net margin stands at -5.7%, down from 16.9% several years earlier. PolyPeptide Group currently offers a dividend yield of about 0.64%. The payout ratio is around 137% of earnings. Analysts set a median price target of 40.01 EUR, implying 14.9% below the current price. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus.
PolyPeptide Group stock price
PolyPeptide Group business model & stock analysis
Frequently asked questions about PolyPeptide Group
The business model of PolyPeptide Group AG, a leading contract manufacturing organization, focuses on producing custom-made peptides and peptide-based drugs for pharmaceutical companies worldwide. With over 60 years of expertise, PolyPeptide offers a comprehensive range of integrated services, including peptide synthesis, manufacturing, and analytical development. By leveraging their state-of-the-art facilities and cutting-edge technologies, the company ensures high-quality standards and regulatory compliance. PolyPeptide's skilled team collaborates closely with clients at every stage of the development process, from research and development to commercial production. Through their dedication to innovation and customer satisfaction, PolyPeptide Group AG strives to be the preferred partner for peptide-based therapeutic solutions.
PolyPeptide Group AG is primarily active in the pharmaceutical industry.
The main competitors of PolyPeptide Group AG in the market include companies such as Bachem Holding AG, Lonza Group Ltd., and CordenPharma International.
PolyPeptide Group AG is a renowned company engaged in the development and manufacturing of peptide-based drugs. Established in [year], PolyPeptide Group AG has emerged as a global leader in this field. With its cutting-edge research and development capabilities, the company has successfully catered to diverse industries, including pharmaceuticals, biotechnology, and cosmetics. PolyPeptide Group AG's commitment to excellence, innovation, and customer satisfaction has helped it forge strong partnerships with leading companies worldwide. Leveraging its extensive expertise, PolyPeptide Group AG continues to revolutionize the peptide industry, driving advancements in therapeutics and creating a meaningful impact on patients' lives globally.
PolyPeptide Group AG has achieved several significant milestones. To begin with, the company successfully expanded its global reach by establishing state-of-the-art production facilities in India and Sweden. Additionally, PolyPeptide Group AG has consistently delivered high-quality peptide-based solutions for pharmaceutical and biotech companies worldwide. The company also received regulatory approvals for several innovative peptide therapeutics, further strengthening its position in the market. Furthermore, PolyPeptide Group AG has collaborated with renowned industry leaders, facilitating the development of cutting-edge therapies. Overall, the company's commitment to innovation, global expansion, and strategic partnerships has led to its remarkable achievements in the field of peptide-based solutions.
PolyPeptide Group AG is primarily present in multiple countries and regions worldwide, ensuring a global reach for its operations. This Swiss-based company has established a strong presence in Europe, with facilities in Belgium, France, Sweden, and Switzerland. Additionally, PolyPeptide Group AG operates in the United States, with manufacturing facilities in California and Scandinavia. The company's broad geographical presence allows it to cater to a diverse client base and strengthen its position as a leading provider of peptide-based solutions in the pharmaceutical and biotech industries.
PolyPeptide Group AG represents a strong commitment to excellence and innovation in the pharmaceutical industry. With a focus on peptide manufacturing, the company strives to deliver high-quality products and services to its customers. PolyPeptide Group AG values scientific expertise, customer satisfaction, and compliance with regulatory standards. Their corporate philosophy emphasizes collaboration, integrity, and sustainable practices. Through their cutting-edge research and development, the company aims to contribute to the advancement of healthcare. By consistently delivering innovative peptide solutions, PolyPeptide Group AG has established itself as a trusted leader in the industry.
Analysts currently set an average price target of 39.77 EUR for the PolyPeptide Group stock (median: 40.01 EUR), implying -15.4 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the PolyPeptide Group stock: 11 recommend buying, 1 holding and 1 selling. For 2026, analysts expect PolyPeptide Group to generate revenue of 497.84 M EUR and earnings per share of 0.87 EUR.
The PolyPeptide Group share (PPGN.SW) is listed on 3 stock exchanges, including: London (0AAJ.L), SIX (Zürich) (PPGN.SW).
The PolyPeptide Group AG is an internationally active company based in Switzerland. Founded in 1952, it specializes in the production of peptides and proteins for the pharmaceutical industry. PolyPeptide's business model is based on the production and marketing of pharmaceutical peptides and proteins for clinical applications and research. The company offers its customers a wide range of products and services, including: - Synthetic production of peptides and proteins for the pharmaceutical industry. - Research services for the development of peptide-based drugs and diagnostics. - Custom manufacturing of peptides and proteins for research and development. - Production of therapeutic peptides and proteins for clinical applications. To provide these services, PolyPeptide operates production facilities in Sweden, France, India, and the United States. These locations allow the company to quickly respond to the needs of its customers and offer the best solutions for their specific requirements. PolyPeptide's divisions can be described as follows: - Pharmaceutical Peptides: PolyPeptide produces pharmaceutical peptides for clinical applications. This includes drugs for the treatment of cancer, diabetes, autoimmune diseases, and infectious diseases. - Research Peptides: PolyPeptide supplies peptides for research and development of drugs and diagnostics. These peptides allow the research community to gain new insights into molecular processes in the body. - Custom Peptides: The company manufactures custom peptides for research and development. This service is aimed at customers in science and industry who need tailored peptides for their specific applications. - Manufacturing of Therapeutic Proteins: PolyPeptide is a leading provider of therapeutic proteins and peptides for the pharmaceutical industry. This includes drugs for the treatment of cancer, neurological disorders, and metabolic diseases. PolyPeptide focuses on developing innovative peptides and proteins for the pharmaceutical industry. Through continuous research and development and collaboration with industry customers, the company is able to offer its customers the latest products and services. In addition, PolyPeptide emphasizes quality and reliability. All products are manufactured according to the highest quality standards and undergo strict controls. This gives customers the assurance that they will always receive products of the highest quality. Conclusion: The PolyPeptide Group AG is a leading provider of peptides and proteins for the pharmaceutical industry. With its wide range of products and its focus on innovation, quality, and reliability, PolyPeptide is a trusted partner for its customers in the industry and the scientific community.
The expected revenue of PolyPeptide Group is 497.84 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of PolyPeptide Group is 28.57 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of PolyPeptide Group is currently 54.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PolyPeptide Group stock.
The price-to-sales ratio (P/S) of PolyPeptide Group is currently 3.12. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PolyPeptide Group stock.
The Eulerpool Quality Score for PolyPeptide Group is 2/10.
The ISIN of PolyPeptide Group is CH1110760852. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of PolyPeptide Group is PPGN.SW. The ticker symbol is used to trade PolyPeptide Group shares on the stock exchange.
PolyPeptide Group stock
PolyPeptide Group Peer Group
PolyPeptide Group Ticker
PolyPeptide Group FIGI
All fundamentals and in-depth analysis of PolyPeptide Group
Our stock analysis for PolyPeptide Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PolyPeptide Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.